An open-label study of aripiprazole in nonschizophrenic crack-dependent patients.
Vorspan
Florence
F
Bellais
Laetitia
L
Keijzer
Lenneke
L
Lépine
Jean-Pierre
JP
D000328:Adult; D014150:Antipsychotic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000068180:Aripiprazole; D019970:Cocaine-Related Disorders / Q000188:drug therapy* / Q000534:rehabilitation; D016578:Crack Cocaine / Q000009:adverse effects; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010879:Piperazines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D015363:Quinolones / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D016320:Substance Abuse Treatment Centers
D014150:Antipsychotic Agents; D016578:Crack Cocaine; D010879:Piperazines; D015363:Quinolones; D000068180:Aripiprazole